Gelteq Ltd.

General Information
Business:	We are a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, pet care, nutriceuticals and other products. (Incorporated in Australia) A “white label” gel-based delivery solution is where we produce a product that other companies rebrand as their own product. Our principal products are edible gels, which we refer to as gels, and their application in gel-based dosage forms. Our current product suite consists of multiple products that sit within five core verticals — pets, sports, pharmaceutical (pharma), over-the-counter (OTC) and nutriceutical — all of which leverage our patent- pending multiple-ingredient dosage forms, and which we expect to have a wide range of applications and consumers. We currently focus our efforts on out-licensing our technology to companies to develop and create new products they can manufacture and sell within their established and researched markets, while we continue to manufacture our existing products under license (white label). Note: Net loss and revenue figures are in U.S. dollars (converted from Australian dollars) for the 12 months that ended March 31, 2024. Note: For the year that ended June 30, 2023, Gelteq Ltd. reported a net loss of US$3.51 million on revenue (defined as “revenue from contracts with customers”) of about US$79,843, according to the prospectus. Note: For the year that ended June 30, 2022, Gelteq Ltd. reported a net loss of US$3.37 million on revenue of about US$147,536, according to the prospectus. (Note: The Benchmark Company was named the sole book-runner, replacing EF Hutton, in an F-1/A filing dated Sept. 12, 2024.)* (Note: Gelteq Ltd. priced its IPO at $4.00 and sold 1.3 million shares – the terms in the prospectus – to raise $5.2 million on Monday night, Oct. 28, 2024.) (Note: Gelteq Ltd. updated its IPO filing on Oct. 22, 2024, with a Form 424B4 filing (prospectus) stating that the assumed IPO price is $4.00 – down from $5.00 in the previous F-1/A filing – and keeping the number of shares at 1.3 million Class A ordinary shares – to raise $5.2 million.) (Background: Gelteq Ltd. is offering 1.3 million Class A ordinary shares at $5.00 to raise $6.5 million – the terms that it disclosed in its F-1 dated Aug. 30, 2022. This is a NASDAQ listing. Background: The Melbourne, Australia-based company filed confidential IPO documents on March 31, 2022.)
Industry:	Pharmaceuticals
Employees:	8
Founded:	2018
Contact Information
Address	Level 4 100 Albert Road South Melbourne VIC, 3025 Australia
Phone Number	+61 3 9087 3990
Web Address	http://www.gelteq.com/
View Prospectus:	Gelteq Ltd.
Financial Information
Market Cap	$37.75mil
Revenues	$0.0 mil (last 12 months)
Net Income	$-3.36 mil (last 12 months)
IPO Profile
Symbol	GELS
Exchange	NASDAQ
Shares (millions):	1.3
Price range	$4.00 - $4.00
Est. $ Volume	$5.2 mil
Manager / Joint Managers	The Benchmark Company
CO-Managers
Expected To Trade:	10/29/2024
Status:	Priced
Quiet Period Expiration Date:	Available only to Subscribers
Lock-Up Period Expiration Date:	Available only to Subscribers
SCOOP Rating	Available only to Subscribers
Rating Change	Available only to Subscribers

We are a clinical and science-based company that is focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, pet care, nutriceuticals and other products. (Incorporated in Australia)

*Note: Net loss and revenue figures are in U.S. dollars (converted from Australian dollars) for the 12 months that ended March 31, 2024.

*Note: For the year that ended June 30, 2023, Gelteq Ltd. reported a net loss of US$3.51 million on revenue (defined as “revenue from contracts with customers”) of about US$79,843, according to the prospectus.

*Note: For the year that ended June 30, 2022, Gelteq Ltd. reported a net loss of US$3.37 million on revenue of about US$147,536, according to the prospectus.

(Note: The Benchmark Company was named the sole book-runner, replacing EF Hutton, in an F-1/A filing dated Sept. 12, 2024.)

(Note: Gelteq Ltd. priced its IPO at $4.00 and sold 1.3 million shares – the terms in the prospectus – to raise $5.2 million on Monday night, Oct. 28, 2024.)

(Note: Gelteq Ltd. updated its IPO filing on Oct. 22, 2024, with a Form 424B4 filing (prospectus) stating that the assumed IPO price is $4.00 – down from $5.00 in the previous F-1/A filing – and keeping the number of shares at 1.3 million Class A ordinary shares – to raise $5.2 million.)

(Background: Gelteq Ltd. is offering 1.3 million Class A ordinary shares at $5.00 to raise $6.5 million – the terms that it disclosed in its F-1 dated Aug. 30, 2022. This is a NASDAQ listing. Background: The Melbourne, Australia-based company filed confidential IPO documents on March 31, 2022.)